Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapiesBranko Cuglievan, Naveen Pemmaraju, Adam J. Lamble et al.|Leukemia|2023Cited by 52
ALL-808 Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic LeukemiaElias Jabbour, Hagop Kantarjian, Nicholas J. Short et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 7
SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaFadi Haddad, Hagop M. Kantarjian, Elias Jabbour et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 7
Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular FeaturesWalid Macaron, Nicholas J. Short, Elias Jabbour et al.|Blood|2024Cited by 5
Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First RemissionAlexandre Bazinet, Tapan M. Kadia, Naval Daver et al.|Blood|2024Cited by 4